Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 12/20 | 0.40 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.38 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.36 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.36 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.36 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL984599 | 0.91 | BTK (0.39) | BTKMRGPRX1 | |
| SCHEMBL986391 | 0.91 | CDK9 (0.41) | BTKCYP4F2CYP4A11ADORA2AADORA1 | |
| SCHEMBL985350 | 0.91 | CDK9 (0.41) | BTKCYP4F2CYP4A11ADORA2AADORA1 | |
| SCHEMBL983586 | 0.90 | BTK (0.35) | BTKMRGPRX1TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL983264 | 0.90 | BTK (0.40) | BTKMRGPRX1TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL983559 | 0.90 | PTK2 (0.39) | MRGPRX1KMT2APTK2 | |
| SCHEMBL983145 | 0.90 | BTK (0.44) | BTKTAS1R3TAS1R1TAS1R2KMT2A | |
| SCHEMBL987097 | 0.90 | CNR1 (0.38) | BTKADORA2AADORA1TAS1R3TAS1R1 | |
| SCHEMBL984600 | 0.90 | BTK (0.40) | BTKKMT2A | |
| SCHEMBL984446 | 0.90 | BTK (0.40) | BTKCYP4F2CYP4A11ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110021479-A1 | PYRROLOPYRIMIDINECARBOXAMIDES | NYCOMED GMBH (DE) | 2011-01-27 | — | — | US | claimed |
| US-20110021479-A1 | PYRROLOPYRIMIDINECARBOXAMIDES | NYCOMED GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021479-A1 | PYRROLOPYRIMIDINECARBOXAMIDES | PDE5A, PDE3A, PDE2A | BTK 1977/4885CYP4F2 334/4885CYP4A11 416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.